Side effects of dermato-oncologic therapies
Dermatologie (Heidelberg, Germany), 2024 - europepmc.org
Background Immune checkpoint inhibitors (ICIs) such as PD (L) 1 and CTLA4 antibodies as
well as targeted therapies such as BRAF and MEK inhibitors have significantly improved the …
well as targeted therapies such as BRAF and MEK inhibitors have significantly improved the …
Side effects of dermato-oncologic therapies
JC Hassel, L Zimmer - Dermatologie (Heidelberg, Germany) - pubmed.ncbi.nlm.nih.gov
Zusammenfassung HINTERGRUND: Immuncheckpointblocker (ICB) wie PD-(L) 1-und CTLA-
4-Antikörper sowie zielgerichtete Therapeutika wie BRAF (v-raf murine sarcoma viral …
4-Antikörper sowie zielgerichtete Therapeutika wie BRAF (v-raf murine sarcoma viral …